LI
CPRX

Leap Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Leap Investments’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$158K Sell
34,300
-35,200
-51% -$158K 0.1% 323
2020
Q1 		$268K Buy
+69,500
New +$285K 0.39% 83

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Leap Investments's CPRX Position: Q2 2020 in Review

Leap Investments reduced its Catalyst Pharmaceutical (CPRX) stake by 51% in Q2 2020, selling an estimated $158K and leaving 34,300 shares worth $158K. The position accounts for 0.1% of the portfolio, ranked #323.

Leap Investments first reported a position in CPRX in Q1 2020 and has held it in 2 quarters since. The position peaked at $268K in Q1 2020. 140 funds tracked by Wall St. Rank hold CPRX as of Q2 2020.

  • Leap Investments held 34,300 shares of Catalyst Pharmaceutical worth $158K as of Q2 2020.
  • Leap Investments sold 35,200 Catalyst Pharmaceutical shares in Q2 2020, an estimated $158K.
  • Catalyst Pharmaceutical made up 0.1% of Leap Investments's portfolio in Q2 2020, its #323 holding.
  • Leap Investments first reported a position in Catalyst Pharmaceutical in Q1 2020 and has held it in 2 quarters since.
  • Leap Investments's Catalyst Pharmaceutical position peaked at $268K in Q1 2020.
  • 140 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.